No effect of taurine on platelet aggregation in men with a predisposition to type 2 diabetes mellitus

Abstract

Abbreviations

ADP–denosine diphosphate; BMI–body mass index; FFA–free fatty acids; FFM–fat-free mass; IGT–impaired glucose tolerance; OGTT–oral glucose tolerance test; PPP–platelet-poor plasma; PRP–platelet-rich plasma; T2DM–type 2 diabetes mellitus; TG–triglyceride.

Contributed equally to this study.

Any diet therapy that potentially could affect platelet function would also influence the initiation of atherosclerotic plaque formation which is an important complication of diabetes mellitus eventually resulting in myocardial infarction and stroke. Blood platelets are rich in taurine, and it has been shown that taurine inhibits platelet aggregation in healthy subjects. The purpose was to examine the effect of taurine supplementation on platelet aggregation in high-risk subjects with a positive family history of T2DM. Twenty healthy men were included in a double-blinded, randomized, crossover study, receiving daily supplementation of 1.5 g taurine or placebo for two 8-week periods. Subjects were overweight and first-degree relatives of T2DM patients. At the end of each treatment, fasting blood samples for assessment of platelet aggregation was drawn. Platelet aggregation was induced by ADP. Plasma taurine concentration was significantly greater after taurine intervention compared to placebo (131.4 ± 61.7 vs. 38.9 ± 6.7 µmol/l, P < 0.0001). There was no difference in the threshold level for complete platelet aggregation induced by ADP in vivo between placebo and taurine intervention (placebo 3.86 ± 2.21 vs. taurine 3.86 ± 3.25 µmol/l). Supplementation with 1.5 g of taurine for 8 weeks had no effect on platelet aggregation in overweight prediabetic men.

• Platelet aggregation
• T2DM
• taurine
• ADP